Healthcare Providers and Services
Company Overview of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center is a cancer care hospital that engages in cancer prevention, treatment, research, and education. It offers a range of programs to help patients and families throughout various phases of treatment, including genetic counseling, rehabilitation, integrative medicine, counseling, pain and palliative care, cancer screening, and assistance in navigating life after treatment. The company provides childhood cancer treatments, including blood and marrow transplantation, pediatric surgery, and subspecialty services; and treatments for adolescents and young adults with various types of cancers. Its research areas include cancer biology and genetics, cell biology, ...
1275 York Avenue
New York, NY 10065
Founded in 1884
Key Executives for Memorial Sloan Kettering Cancer Center
Chief Executive Officer and President
Senior Vice President of Finance
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2014.
Memorial Sloan Kettering Cancer Center Key Developments
IBM Research Scientists Investigate Use of Cognitive Computing-Based Visual Analytics for Skin Cancer Image Analysis with Memorial Sloan Kettering
Dec 17 14
IBM announced a collaboration with Memorial Sloan Kettering to research the application of cognitive computing to analyze dermatological images of skin lesions with the goal of assisting clinicians in the identification of various cancerous disease states. The technology, which learns by identifying specific patterns in medical images, has the potential to increase the number of cases detected and help clinicians make earlier diagnoses. The automated analysis of skin imaging is one area of research that is currently being investigated by IBM Research, in conjunction with a larger international effort being led by Memorial Sloan Kettering.
Memorial Sloan-Kettering Cancer Center Presents at Life Sciences Summit 2014, Oct-28-2014 through Oct-29-2014
Oct 22 14
Memorial Sloan-Kettering Cancer Center Presents at Life Sciences Summit 2014, Oct-28-2014 through Oct-29-2014. Venue: 10 on the Park at Time Warner Center, 60 Columbus Circle, 10th Floor, New York, NY 10019, United States. Presentation Date & Speakers: Oct-28-2014, David B. Solit, MD, Geoffrey Beene Chair, Director, Center for Molecular Oncology, Jae Park, MD, Medical Oncologist.
Atara Biotherapeutics Enters into Immunotherapy Alliance with Memorial Sloan Kettering Cancer Center to Develop and Commercialize Allogeneic T-cell Therapies
Sep 24 14
Atara Biotherapeutics has entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center to develop and commercialize allogeneic T-cell therapies to treat certain cancers and persistent viral infections. As part of the deal, Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies. These therapies include T-cells activated against Epstein Barr Virus, or EBV (Phase 2); T-cells activated against cytomegalovirus, or CMV (Phase 2); and T-cells activated against Wilms Tumor 1, or WT1 (Phase 1). These three programs share a common technology under which third-party donor-derived whole blood is collected and enriched for T lymphocytes (T-cells), which are then exposed to certain antigens, and the resulting activated T-cells are characterized and stored for future therapeutic use. Under the deal, MSK will receive cash and Atara common stock in return for the exclusive option. In case Atara exercises its option to enter into the license deal, MSK will receive an upfront license payment and will be eligible to secure additional payments based on achievement of certain development, regulatory and sales-related milestones as well as royalty payments. Both the firms have agreed to collaborate on further research to develop additional cellular therapies, which may include T-cell therapies against other antigens and/or chimeric antigen receptor-modified T-cells, known as CAR-T.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|